Japanese Pharma Stock Sinks Amid COVID-19 Treatment

The drug was originally effective against SARS-CoV-1

Deputy Editor
Mar 10, 2020 at 10:27 AM
facebook X logo linkedin

Shares of AIM Immunotech Inc (NYSE:AIM) were last seen trading down 22.5% at $4.73, despite yesterday announcing that the National Institute of Infectious Diseases (NIID) in Japan will begin testing its drug Ampligen, a broad-spectrum antiviral, as a potential treatment for the new coronavirus outbreak. Researchers are optimistic about the efficacy of this new treatment due to the drugs previous positive reaction with the original SARS coronavirus (SARS-CoV-1).

Despite today's plunge, the stock is up a whopping 644% year-to-date and earlier last week saw a notable bounce off the supportive 10-day moving average. Heading into today, all three covering analysts sport a "buy" recommendation. First thing this morning Alliance Global Partners also chimed in, saying it will maintain its "buy" rating and hiked its price target to $6.50 from $2.76.

Currently, AIM’s short interest of 1.01 million shares accounts for a healthy 13.1% of its total available float. At the equity's average pace of trading, it would take under a week for short sellers to buy back their bearish bets.


Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.

Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!




Rainmaker Ads CGI